Overview

Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

Status:
Not yet recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, double-blinded, placebo-controlled study for subjects with evidence of PSCI.
Phase:
Phase 2
Details
Lead Sponsor:
AZTherapies, Inc.
Collaborators:
APCER
MedAvante
Pharma Consulting Group (PCG)
Treatments:
Cromolyn Sodium